Vernal Keratoconjunctivitis Market
Market Insights on Vernal Keratoconjunctivitis covering sales outlook, demand forecast & up-to-date key trends
Vernal Keratoconjunctivitis Market By Treatment, Dosage Type, Drug Form, Distribution Channel & Region – Forecast 2023–2033
Vernal Keratoconjunctivitis Market Snapshot (2023-2033)
The global Vernal Keratoconjunctivitis Market is expected to garner a market value of US$ 436.9 Million in 2023 and is expected to accumulate a market value of US$ 782.42 Million by registering a CAGR of 6% in the forecast period 2023-2033. One of the reasons driving the global market over the projection period is the rising incidence of conjunctivitis in emerging nations. The market for Vernal Keratoconjunctivitis registered a CAGR of 4% in the historical period 2017-2022.
Clinical examinations and procedures are carried out to diagnose the condition, which aids medical professionals in making additional decisions about medicine, testing, and recuperation and is expected to accelerate market expansion throughout the projection period.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 436.9 Million |
|
Anticipated Forecast Value (2033) |
US$ 782.42 Million |
|
Projected Growth Rate (2023-2033) |
6% CAGR |
Let us know your requirement to get
100% FREE customization
2017-2022 Vernal Keratoconjunctivitis Market Demand Analysis vs. Forecast 2023-2033
According to market research and competitive intelligence provider Future Market Insights- the market for Vernal Keratoconjunctivitis reflected a value of 4% during the historical period, 2017-2022. According to the NCBI article published in August 2021, conjunctivitis can manifest in COVID-19-infected people. Thus, increasing prevalence of conjunctivitis during the pandemic had the potential to drive the demand for the market.
However, the relaxation of strict lockdowns started to contribute to the increase in the patient inflow for vernal keratoconjunctivitis treatment, adding to the growth of the market. Thus, the market for Vernal Keratoconjunctivitis is expected to register a CAGR of 6% in the forecast period 2023-2033.
Which are Some Prominent Drivers of the Vernal Keratoconjunctivitis Market?
Increasing incidence of Vernal Keratoconjunctivitis disease to push the market growth
The increasing prevalence of Vernal Keratoconjunctivitis disease is one of the biggest drivers of the market. As per the Nature article published in April 2022, approximately 10% of the sample population had allergic conjunctivitis. In India, the prevalence of allergic conjunctivitis was 12.22% among those aged between five and 15 years.
Also, the NCBI article published in January 2021 mentioned that more than half of the patients report daily symptoms as seasonal or perennial and around 75% consider their symptoms to be severe. The same source also mentioned that there were between 1.2 and 10.6 cases of vernal keratoconjunctivitis per 10,000 individuals in Europe.
With the increasing prevalence and awareness of ocular allergies has significantly increased owing to several factors such as faster urbanization and a growing number of allergens. Treatment for vernal keratoconjunctivitis includes oral or over-the-counter (OTC) drugs that reduce the release of histamine. Also, anti-inflammatory or anti-inflammation eye drops are available quickly and are found to relieve acute conjunctivitis. Hence, this segment is expected to witness steady growth during the forecast period.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Vernal Keratoconjunctivitis Market?
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Vernal Keratoconjunctivitis, less awareness of Vernal Keratoconjunctivitis disease, and insubstantial treatment options are hampering the market growth. The global conjunctivitis market is anticipated to be constrained by factors such as low illness awareness and inadequate pharmaceutical coverage in developing nations.
Region-Wise Insights
How is the Market for Vernal Keratoconjunctivitis Turning Out in the Asia Pacific Region?
Improvement in healthcare spending propelling growth of Vernal Keratoconjunctivitis in Asia Pacific
The Asia Pacific is expected to exhibit the fastest growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of ocular allergies in the region. Conjunctivitis is quite prevalent in nations like India. For instance, the state of Tamil Nadu reported a viral conjunctivitis issue among students and workers at schools. Clinical Epidemiology and Global Health, for instance, estimated that 12.22% of Indians suffer from ocular allergies. The male segment is projected to have a higher prevalence (13.44%) than females (10.71%). During the projected period, these trends are anticipated to support market expansion in the region.
In addition to these factors, an increase in the frequency of infections, poor hygienic conditions in developing nations, and protracted deliveries in several of the region's countries, the Asia Pacific region is anticipated to have the third-largest share. In addition, it is anticipated that the expanding medical tourism sector in nations like Malaysia, China, and India would increase demand for treatment. Over the anticipated time, these factors will boost market expansion in the region.
What are the Factors Boosting the Market for Vernal Keratoconjunctivitis in North America?
High prevalence of ophthalmic allergies shaping landscape for Vernal Keratoconjunctivitis in North America
North America is anticipated to acquire a market share of about 20% in the forecast period. This growth is attributable to the increasing awareness of ophthalmic allergies. This, coupled with the existence of majority players, which leads to novel and advanced drug launches, and the robust spread of this disease, are factors attributing to the market's growth. A country like the United States has a major presence of positive reimbursement policies, and this is the key reason for this region's dominance in this market.
As per the National Library Medicine article published in February 2020, conjunctivitis affects more than 6 million people across the United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer.
Such prevalence of conjunctivitis in the United States is pushing the demand for an effective treatment, thereby contributing to the market's growth during the forecast period.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-Wise Insights
Based on Dosage Form, Which Segment is Pushing the Market Growth?
Superior efficiency of tablet consumption bolstering the growth
On the basis of treatment, the segment has been divided into gel, ointment, tablets and others. The tablets are widely used by patients suffering from vernal keratoconjunctivitis which is further triggering the market growth. Owing to an increased usage of these tablets in the treatment, as they help in the faster recovery of the disease, players are focussing on launching new and sophisticated products.
Start-Up in the Vernal Keratoconjunctivitis Market
Key start-up players in the Vernal Keratoconjunctivitis market are-
- In March 2022, Visus Therapeutics Inc., a clinical-stage pharmaceutical company aims to create an inventive ophthalmic therapy to enhance vision for individuals across the globe. The company announced the launch of the first of two pivotal Phase 3 trials (BRIO-I and BRIO-II) for its lead asset, BRIMOCHOL™ PF, which is a topical preservative-free ophthalmic solution for treating presbyopia.
- In October 2021, Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company and SparingVision, a genomic medicine company developing vision saving treatments for ocular diseases, announced a strategic collaboration to develop innovative genomic medicines using CRISPR/Cas9 technology for treating ocular diseases.
Market Competition
Key players in the Vernal Keratoconjunctivitis market are Allakos, iCo Therapeutics, Akari Therapeutics, and Santen.
- In May 2022 Santen Pharmaceutical received approval for Verkazia from the National Medical Products Administration (NMPA) in China through its legal entity for treating severe vernal keratoconjunctivitis (VKC) in children and adolescents aged four years and above.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 436.9 Million |
|
Market Value in 2033 |
US$ 782.42 Million |
|
Growth Rate |
CAGR of 6% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2017-2022 |
|
Forecast Period |
2023-2033 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2023-2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
Allakos, iCo Therapeutics, Akari Therapeutics, and Santen |
|
Customization |
Available Upon Request |
Key Segments Profiled in the Vernal Keratoconjunctivitis Industry Survey
Treatment:
- Mast Cell Stabilizers
- Antihistamines
- Nonsteroidal Anti-inflammatory Drugs - NSAIDs
- Topical Corticosteroids
- Cyclosporine
- Tacrolimus
- Others
Drug Type:
- Bertilimumab
- Verkazia
- Lodoxamide
- Tacrolimus
- Antolimab
- Nomacopan
- Others
Dosage form:
- Ointment
- Gel
- Tablets
- Others
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Latin America
- Europe
- Asia Pacific
- MEA
Frequently Asked Questions
From 2017-2022, the Vernal Keratoconjunctivitis market grew at CAGR of 4%.
The global Vernal Keratoconjunctivitis market is expected to grow with a 6% CAGR during 2023-2033.
As of 2033, the Vernal Keratoconjunctivitis market is expected to reach US$ 782.42 Million
According to the FMI analysis, Hospital pharmacies account for the largest market share.
Tablets are expected to show the highest CAGR owing to the increasing demand for new approaches.
North America is expected to possess 20% market share for the Vernal Keratoconjunctivitis market.
The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018-2022 and Forecast, 2023-2033
4.1. Historical Market Size Value (US$ Mn) Analysis, 2018-2022
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Type, 2018-2022
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Type, 2023-2033
5.3.1. Bertilimumab
5.3.2. Verkazia
5.3.3. Lodoxamide
5.3.4. Tacrolimus
5.3.5. Antolimab
5.3.6. Nomacopan
5.3.7. Others
5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018-2022
5.5. Absolute $ Opportunity Analysis By Drug Type, 2023-2033
6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Treatment
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Treatment, 2018-2022
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment, 2023-2033
6.3.1. Mast Cell Stabilizers
6.3.2. Antihistamines
6.3.3. Nonsteroidal Anti-inflammatory Drugs - NSAIDs
6.3.4. Topical Corticosteroids
6.3.5. Cyclosporine
6.3.6. Tacrolimus
6.3.7. Others
6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018-2022
6.5. Absolute $ Opportunity Analysis By Treatment, 2023-2033
7. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Dosage Form
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Dosage Form , 2018-2022
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Dosage Form , 2023-2033
7.3.1. Gel
7.3.2. Ointment
7.3.3. Tablet
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By Dosage Form , 2018-2022
7.5. Absolute $ Opportunity Analysis By Dosage Form , 2023-2033
8. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2018-2022
8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2023-2033
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018-2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023-2033
9. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018-2022
9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. Asia Pacific
9.3.5. MEA
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
10.2.1. By Country
10.2.1.1. U.S.
10.2.1.2. Canada
10.2.2. By Drug Type
10.2.3. By Treatment
10.2.4. By Dosage Form
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Type
10.3.3. By Treatment
10.3.4. By Dosage Form
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Type
11.2.3. By Treatment
11.2.4. By Dosage Form
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Type
11.3.3. By Treatment
11.3.4. By Dosage Form
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. U.K.
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Drug Type
12.2.3. By Treatment
12.2.4. By Dosage Form
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Type
12.3.3. By Treatment
12.3.4. By Dosage Form
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. Asia Pacific Market Analysis 2018-2022 and Forecast 2023-2033, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.1.4. Singapore
13.2.1.5. Thailand
13.2.1.6. Indonesia
13.2.1.7. Australia
13.2.1.8. New Zealand
13.2.1.9. Rest of Asia Pacific
13.2.2. By Drug Type
13.2.3. By Treatment
13.2.4. By Dosage Form
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Type
13.3.3. By Treatment
13.3.4. By Dosage Form
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Country
14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Drug Type
14.2.3. By Treatment
14.2.4. By Dosage Form
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Type
14.3.3. By Treatment
14.3.4. By Dosage Form
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Drug Type
15.1.2.2. By Treatment
15.1.2.3. By Dosage Form
15.1.2.4. By Distribution Channel
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Drug Type
15.2.2.2. By Treatment
15.2.2.3. By Dosage Form
15.2.2.4. By Distribution Channel
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Drug Type
15.3.2.2. By Treatment
15.3.2.3. By Dosage Form
15.3.2.4. By Distribution Channel
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Drug Type
15.4.2.2. By Treatment
15.4.2.3. By Dosage Form
15.4.2.4. By Distribution Channel
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Drug Type
15.5.2.2. By Treatment
15.5.2.3. By Dosage Form
15.5.2.4. By Distribution Channel
15.6. U.K.
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Drug Type
15.6.2.2. By Treatment
15.6.2.3. By Dosage Form
15.6.2.4. By Distribution Channel
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Drug Type
15.7.2.2. By Treatment
15.7.2.3. By Dosage Form
15.7.2.4. By Distribution Channel
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Drug Type
15.8.2.2. By Treatment
15.8.2.3. By Dosage Form
15.8.2.4. By Distribution Channel
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Drug Type
15.9.2.2. By Treatment
15.9.2.3. By Dosage Form
15.9.2.4. By Distribution Channel
15.10. China
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Drug Type
15.10.2.2. By Treatment
15.10.2.3. By Dosage Form
15.10.2.4. By Distribution Channel
15.11. Japan
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Drug Type
15.11.2.2. By Treatment
15.11.2.3. By Dosage Form
15.11.2.4. By Distribution Channel
15.12. South Korea
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Drug Type
15.12.2.2. By Treatment
15.12.2.3. By Dosage Form
15.12.2.4. By Distribution Channel
15.13. Singapore
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Drug Type
15.13.2.2. By Treatment
15.13.2.3. By Dosage Form
15.13.2.4. By Distribution Channel
15.14. Thailand
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Drug Type
15.14.2.2. By Treatment
15.14.2.3. By Dosage Form
15.14.2.4. By Distribution Channel
15.15. Indonesia
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Drug Type
15.15.2.2. By Treatment
15.15.2.3. By Dosage Form
15.15.2.4. By Distribution Channel
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Drug Type
15.16.2.2. By Treatment
15.16.2.3. By Dosage Form
15.16.2.4. By Distribution Channel
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Drug Type
15.17.2.2. By Treatment
15.17.2.3. By Dosage Form
15.17.2.4. By Distribution Channel
15.18. GCC Countries
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Drug Type
15.18.2.2. By Treatment
15.18.2.3. By Dosage Form
15.18.2.4. By Distribution Channel
15.19. South Africa
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Drug Type
15.19.2.2. By Treatment
15.19.2.3. By Dosage Form
15.19.2.4. By Distribution Channel
15.20. Israel
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Drug Type
15.20.2.2. By Treatment
15.20.2.3. By Dosage Form
15.20.2.4. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug Type
16.3.3. By Treatment
16.3.4. By Dosage Form
16.3.5. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Santen
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Novartis Pharmaceuticals
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Senju Pharmaceutical
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Allakos
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. iCo Therapeutics
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Akari Therapeutics
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Alcon Vision LLC
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2018-2033
Table 2: Global Market Value (US$ Mn) Forecast by Drug Type, 2018-2033
Table 3: Global Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 4: Global Market Value (US$ Mn) Forecast by Dosage Form , 2018-2033
Table 5: Global Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033
Table 6: North America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 7: North America Market Value (US$ Mn) Forecast by Drug Type, 2018-2033
Table 8: North America Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 9: North America Market Value (US$ Mn) Forecast by Dosage Form , 2018-2033
Table 10: North America Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033
Table 11: Latin America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 12: Latin America Market Value (US$ Mn) Forecast by Drug Type, 2018-2033
Table 13: Latin America Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 14: Latin America Market Value (US$ Mn) Forecast by Dosage Form , 2018-2033
Table 15: Latin America Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033
Table 16: Europe Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 17: Europe Market Value (US$ Mn) Forecast by Drug Type, 2018-2033
Table 18: Europe Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 19: Europe Market Value (US$ Mn) Forecast by Dosage Form , 2018-2033
Table 20: Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033
Table 21: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 22: Asia Pacific Market Value (US$ Mn) Forecast by Drug Type, 2018-2033
Table 23: Asia Pacific Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 24: Asia Pacific Market Value (US$ Mn) Forecast by Dosage Form , 2018-2033
Table 25: Asia Pacific Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033
Table 26: MEA Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 27: MEA Market Value (US$ Mn) Forecast by Drug Type, 2018-2033
Table 28: MEA Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 29: MEA Market Value (US$ Mn) Forecast by Dosage Form , 2018-2033
Table 30: MEA Market Value (US$ Mn) Forecast by Distribution Channel, 2018-2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Drug Type, 2023-2033
Figure 2: Global Market Value (US$ Mn) by Treatment, 2023-2033
Figure 3: Global Market Value (US$ Mn) by Dosage Form , 2023-2033
Figure 4: Global Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 5: Global Market Value (US$ Mn) by Region, 2023-2033
Figure 6: Global Market Value (US$ Mn) Analysis by Region, 2018-2033
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033
Figure 9: Global Market Value (US$ Mn) Analysis by Drug Type, 2018-2033
Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033
Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033
Figure 12: Global Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 13: Global Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 14: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 15: Global Market Value (US$ Mn) Analysis by Dosage Form , 2018-2033
Figure 16: Global Market Value Share (%) and BPS Analysis by Dosage Form , 2023-2033
Figure 17: Global Market Y-o-Y Growth (%) Projections by Dosage Form , 2023-2033
Figure 18: Global Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033
Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 21: Global Market Attractiveness by Drug Type, 2023-2033
Figure 22: Global Market Attractiveness by Treatment, 2023-2033
Figure 23: Global Market Attractiveness by Dosage Form , 2023-2033
Figure 24: Global Market Attractiveness by Distribution Channel, 2023-2033
Figure 25: Global Market Attractiveness by Region, 2023-2033
Figure 26: North America Market Value (US$ Mn) by Drug Type, 2023-2033
Figure 27: North America Market Value (US$ Mn) by Treatment, 2023-2033
Figure 28: North America Market Value (US$ Mn) by Dosage Form , 2023-2033
Figure 29: North America Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 30: North America Market Value (US$ Mn) by Country, 2023-2033
Figure 31: North America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 34: North America Market Value (US$ Mn) Analysis by Drug Type, 2018-2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033
Figure 37: North America Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 38: North America Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 39: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 40: North America Market Value (US$ Mn) Analysis by Dosage Form , 2018-2033
Figure 41: North America Market Value Share (%) and BPS Analysis by Dosage Form , 2023-2033
Figure 42: North America Market Y-o-Y Growth (%) Projections by Dosage Form , 2023-2033
Figure 43: North America Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033
Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 46: North America Market Attractiveness by Drug Type, 2023-2033
Figure 47: North America Market Attractiveness by Treatment, 2023-2033
Figure 48: North America Market Attractiveness by Dosage Form , 2023-2033
Figure 49: North America Market Attractiveness by Distribution Channel, 2023-2033
Figure 50: North America Market Attractiveness by Country, 2023-2033
Figure 51: Latin America Market Value (US$ Mn) by Drug Type, 2023-2033
Figure 52: Latin America Market Value (US$ Mn) by Treatment, 2023-2033
Figure 53: Latin America Market Value (US$ Mn) by Dosage Form , 2023-2033
Figure 54: Latin America Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 55: Latin America Market Value (US$ Mn) by Country, 2023-2033
Figure 56: Latin America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 59: Latin America Market Value (US$ Mn) Analysis by Drug Type, 2018-2033
Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033
Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033
Figure 62: Latin America Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 65: Latin America Market Value (US$ Mn) Analysis by Dosage Form , 2018-2033
Figure 66: Latin America Market Value Share (%) and BPS Analysis by Dosage Form , 2023-2033
Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Dosage Form , 2023-2033
Figure 68: Latin America Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033
Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 71: Latin America Market Attractiveness by Drug Type, 2023-2033
Figure 72: Latin America Market Attractiveness by Treatment, 2023-2033
Figure 73: Latin America Market Attractiveness by Dosage Form , 2023-2033
Figure 74: Latin America Market Attractiveness by Distribution Channel, 2023-2033
Figure 75: Latin America Market Attractiveness by Country, 2023-2033
Figure 76: Europe Market Value (US$ Mn) by Drug Type, 2023-2033
Figure 77: Europe Market Value (US$ Mn) by Treatment, 2023-2033
Figure 78: Europe Market Value (US$ Mn) by Dosage Form , 2023-2033
Figure 79: Europe Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 80: Europe Market Value (US$ Mn) by Country, 2023-2033
Figure 81: Europe Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 84: Europe Market Value (US$ Mn) Analysis by Drug Type, 2018-2033
Figure 85: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033
Figure 86: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033
Figure 87: Europe Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 88: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 89: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 90: Europe Market Value (US$ Mn) Analysis by Dosage Form , 2018-2033
Figure 91: Europe Market Value Share (%) and BPS Analysis by Dosage Form , 2023-2033
Figure 92: Europe Market Y-o-Y Growth (%) Projections by Dosage Form , 2023-2033
Figure 93: Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033
Figure 94: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 95: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 96: Europe Market Attractiveness by Drug Type, 2023-2033
Figure 97: Europe Market Attractiveness by Treatment, 2023-2033
Figure 98: Europe Market Attractiveness by Dosage Form , 2023-2033
Figure 99: Europe Market Attractiveness by Distribution Channel, 2023-2033
Figure 100: Europe Market Attractiveness by Country, 2023-2033
Figure 101: Asia Pacific Market Value (US$ Mn) by Drug Type, 2023-2033
Figure 102: Asia Pacific Market Value (US$ Mn) by Treatment, 2023-2033
Figure 103: Asia Pacific Market Value (US$ Mn) by Dosage Form , 2023-2033
Figure 104: Asia Pacific Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 105: Asia Pacific Market Value (US$ Mn) by Country, 2023-2033
Figure 106: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 107: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 108: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 109: Asia Pacific Market Value (US$ Mn) Analysis by Drug Type, 2018-2033
Figure 110: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033
Figure 111: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033
Figure 112: Asia Pacific Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 113: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 114: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 115: Asia Pacific Market Value (US$ Mn) Analysis by Dosage Form , 2018-2033
Figure 116: Asia Pacific Market Value Share (%) and BPS Analysis by Dosage Form , 2023-2033
Figure 117: Asia Pacific Market Y-o-Y Growth (%) Projections by Dosage Form , 2023-2033
Figure 118: Asia Pacific Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033
Figure 119: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 120: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 121: Asia Pacific Market Attractiveness by Drug Type, 2023-2033
Figure 122: Asia Pacific Market Attractiveness by Treatment, 2023-2033
Figure 123: Asia Pacific Market Attractiveness by Dosage Form , 2023-2033
Figure 124: Asia Pacific Market Attractiveness by Distribution Channel, 2023-2033
Figure 125: Asia Pacific Market Attractiveness by Country, 2023-2033
Figure 126: MEA Market Value (US$ Mn) by Drug Type, 2023-2033
Figure 127: MEA Market Value (US$ Mn) by Treatment, 2023-2033
Figure 128: MEA Market Value (US$ Mn) by Dosage Form , 2023-2033
Figure 129: MEA Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 130: MEA Market Value (US$ Mn) by Country, 2023-2033
Figure 131: MEA Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 132: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 133: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 134: MEA Market Value (US$ Mn) Analysis by Drug Type, 2018-2033
Figure 135: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033
Figure 136: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033
Figure 137: MEA Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 138: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 139: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 140: MEA Market Value (US$ Mn) Analysis by Dosage Form , 2018-2033
Figure 141: MEA Market Value Share (%) and BPS Analysis by Dosage Form , 2023-2033
Figure 142: MEA Market Y-o-Y Growth (%) Projections by Dosage Form , 2023-2033
Figure 143: MEA Market Value (US$ Mn) Analysis by Distribution Channel, 2018-2033
Figure 144: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 145: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 146: MEA Market Attractiveness by Drug Type, 2023-2033
Figure 147: MEA Market Attractiveness by Treatment, 2023-2033
Figure 148: MEA Market Attractiveness by Dosage Form , 2023-2033
Figure 149: MEA Market Attractiveness by Distribution Channel, 2023-2033
Figure 150: MEA Market Attractiveness by Country, 2023-2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
